The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles

R. Massa, M. B. Panico, S. Caldarola, F. R. Fusco, P. Sabatelli, C. Terracciano, A. Botta, G. Novelli, G. Bernardi, F. Loreni

Research output: Contribution to journalArticle

Abstract

Aims: Myotonic dystrophy type 2 (DM2) is caused by a [CCTG]n intronic expansion in the zinc finger protein 9 (ZNF9) gene. As for DM1, sharing with DM2 a similar phenotype, the pathogenic mutation involves a transcribed but untranslated genomic region, suggesting that RNA toxicity may have a role in the pathogenesis of these multisystem disorders by interfering with common cellular mechanisms. However, haploinsufficiency has been described in DM1 and DM2 animal models, and might contribute to pathogenesis. The aim of the present work was therefore to assess ZNF9 protein expression in rat tissues and in human muscle, and ZNF9 subcellular distribution in normal and DM2 human muscles. Methods: Polyclonal anti-ZNF9 antibodies were obtained in rabbit, high pressure liquid chromatography-purified, and used for Western blot, standard and confocal immunofluorescence and immunogold labelling electron microscopy on a panel of normal rat tissues and on normal and DM2 human muscles. Results: Western blot analysis showed that ZNF9 is ubiquitously expressed in mammalian tissues, and that its signal is not substantially modified in DM2 muscles. Immunofluorescence studies showed a myofibrillar distribution of ZNF9, and double staining with two non-repetitive epitopes of titin located it in the I bands. This finding was confirmed by the visualization of ZNF9 in close relation with sarcomeric thin filaments by immunogold labelling electron microscopy. ZNF9 distribution was unaltered in DM2 muscle fibres. Conclusions: ZNF9 is abundantly expressed in human myofibres, where it is located in the sarcomeric I bands, and no modification of this pattern is observed in DM2 muscles.

Original languageEnglish
Pages (from-to)275-284
Number of pages10
JournalNeuropathology and Applied Neurobiology
Volume36
Issue number4
DOIs
Publication statusPublished - 2010

Fingerprint

Myotonic Dystrophy
Sarcomeres
Zinc Fingers
Muscles
Genes
Proteins
Fluorescent Antibody Technique
Electron Microscopy
Western Blotting
Connectin
Untranslated Regions
Haploinsufficiency
Normal Distribution
Epitopes
Animal Models
High Pressure Liquid Chromatography
RNA
Staining and Labeling
Rabbits
Phenotype

Keywords

  • DM2
  • Immunocytochemistry
  • Myotonic dystrophy type 2
  • Skeletal muscle
  • Zinc finger protein 9
  • ZNF9

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Neurology
  • Histology
  • Physiology (medical)
  • Medicine(all)

Cite this

The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles. / Massa, R.; Panico, M. B.; Caldarola, S.; Fusco, F. R.; Sabatelli, P.; Terracciano, C.; Botta, A.; Novelli, G.; Bernardi, G.; Loreni, F.

In: Neuropathology and Applied Neurobiology, Vol. 36, No. 4, 2010, p. 275-284.

Research output: Contribution to journalArticle

Massa, R. ; Panico, M. B. ; Caldarola, S. ; Fusco, F. R. ; Sabatelli, P. ; Terracciano, C. ; Botta, A. ; Novelli, G. ; Bernardi, G. ; Loreni, F. / The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles. In: Neuropathology and Applied Neurobiology. 2010 ; Vol. 36, No. 4. pp. 275-284.
@article{82756a0572d744c0823f0f54acd166d4,
title = "The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles",
abstract = "Aims: Myotonic dystrophy type 2 (DM2) is caused by a [CCTG]n intronic expansion in the zinc finger protein 9 (ZNF9) gene. As for DM1, sharing with DM2 a similar phenotype, the pathogenic mutation involves a transcribed but untranslated genomic region, suggesting that RNA toxicity may have a role in the pathogenesis of these multisystem disorders by interfering with common cellular mechanisms. However, haploinsufficiency has been described in DM1 and DM2 animal models, and might contribute to pathogenesis. The aim of the present work was therefore to assess ZNF9 protein expression in rat tissues and in human muscle, and ZNF9 subcellular distribution in normal and DM2 human muscles. Methods: Polyclonal anti-ZNF9 antibodies were obtained in rabbit, high pressure liquid chromatography-purified, and used for Western blot, standard and confocal immunofluorescence and immunogold labelling electron microscopy on a panel of normal rat tissues and on normal and DM2 human muscles. Results: Western blot analysis showed that ZNF9 is ubiquitously expressed in mammalian tissues, and that its signal is not substantially modified in DM2 muscles. Immunofluorescence studies showed a myofibrillar distribution of ZNF9, and double staining with two non-repetitive epitopes of titin located it in the I bands. This finding was confirmed by the visualization of ZNF9 in close relation with sarcomeric thin filaments by immunogold labelling electron microscopy. ZNF9 distribution was unaltered in DM2 muscle fibres. Conclusions: ZNF9 is abundantly expressed in human myofibres, where it is located in the sarcomeric I bands, and no modification of this pattern is observed in DM2 muscles.",
keywords = "DM2, Immunocytochemistry, Myotonic dystrophy type 2, Skeletal muscle, Zinc finger protein 9, ZNF9",
author = "R. Massa and Panico, {M. B.} and S. Caldarola and Fusco, {F. R.} and P. Sabatelli and C. Terracciano and A. Botta and G. Novelli and G. Bernardi and F. Loreni",
year = "2010",
doi = "10.1111/j.1365-2990.2010.01068.x",
language = "English",
volume = "36",
pages = "275--284",
journal = "Neuropathology and Applied Neurobiology",
issn = "0305-1846",
publisher = "Wiley Blackwell",
number = "4",

}

TY - JOUR

T1 - The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles

AU - Massa, R.

AU - Panico, M. B.

AU - Caldarola, S.

AU - Fusco, F. R.

AU - Sabatelli, P.

AU - Terracciano, C.

AU - Botta, A.

AU - Novelli, G.

AU - Bernardi, G.

AU - Loreni, F.

PY - 2010

Y1 - 2010

N2 - Aims: Myotonic dystrophy type 2 (DM2) is caused by a [CCTG]n intronic expansion in the zinc finger protein 9 (ZNF9) gene. As for DM1, sharing with DM2 a similar phenotype, the pathogenic mutation involves a transcribed but untranslated genomic region, suggesting that RNA toxicity may have a role in the pathogenesis of these multisystem disorders by interfering with common cellular mechanisms. However, haploinsufficiency has been described in DM1 and DM2 animal models, and might contribute to pathogenesis. The aim of the present work was therefore to assess ZNF9 protein expression in rat tissues and in human muscle, and ZNF9 subcellular distribution in normal and DM2 human muscles. Methods: Polyclonal anti-ZNF9 antibodies were obtained in rabbit, high pressure liquid chromatography-purified, and used for Western blot, standard and confocal immunofluorescence and immunogold labelling electron microscopy on a panel of normal rat tissues and on normal and DM2 human muscles. Results: Western blot analysis showed that ZNF9 is ubiquitously expressed in mammalian tissues, and that its signal is not substantially modified in DM2 muscles. Immunofluorescence studies showed a myofibrillar distribution of ZNF9, and double staining with two non-repetitive epitopes of titin located it in the I bands. This finding was confirmed by the visualization of ZNF9 in close relation with sarcomeric thin filaments by immunogold labelling electron microscopy. ZNF9 distribution was unaltered in DM2 muscle fibres. Conclusions: ZNF9 is abundantly expressed in human myofibres, where it is located in the sarcomeric I bands, and no modification of this pattern is observed in DM2 muscles.

AB - Aims: Myotonic dystrophy type 2 (DM2) is caused by a [CCTG]n intronic expansion in the zinc finger protein 9 (ZNF9) gene. As for DM1, sharing with DM2 a similar phenotype, the pathogenic mutation involves a transcribed but untranslated genomic region, suggesting that RNA toxicity may have a role in the pathogenesis of these multisystem disorders by interfering with common cellular mechanisms. However, haploinsufficiency has been described in DM1 and DM2 animal models, and might contribute to pathogenesis. The aim of the present work was therefore to assess ZNF9 protein expression in rat tissues and in human muscle, and ZNF9 subcellular distribution in normal and DM2 human muscles. Methods: Polyclonal anti-ZNF9 antibodies were obtained in rabbit, high pressure liquid chromatography-purified, and used for Western blot, standard and confocal immunofluorescence and immunogold labelling electron microscopy on a panel of normal rat tissues and on normal and DM2 human muscles. Results: Western blot analysis showed that ZNF9 is ubiquitously expressed in mammalian tissues, and that its signal is not substantially modified in DM2 muscles. Immunofluorescence studies showed a myofibrillar distribution of ZNF9, and double staining with two non-repetitive epitopes of titin located it in the I bands. This finding was confirmed by the visualization of ZNF9 in close relation with sarcomeric thin filaments by immunogold labelling electron microscopy. ZNF9 distribution was unaltered in DM2 muscle fibres. Conclusions: ZNF9 is abundantly expressed in human myofibres, where it is located in the sarcomeric I bands, and no modification of this pattern is observed in DM2 muscles.

KW - DM2

KW - Immunocytochemistry

KW - Myotonic dystrophy type 2

KW - Skeletal muscle

KW - Zinc finger protein 9

KW - ZNF9

UR - http://www.scopus.com/inward/record.url?scp=77952375211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952375211&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2990.2010.01068.x

DO - 10.1111/j.1365-2990.2010.01068.x

M3 - Article

C2 - 20102514

AN - SCOPUS:77952375211

VL - 36

SP - 275

EP - 284

JO - Neuropathology and Applied Neurobiology

JF - Neuropathology and Applied Neurobiology

SN - 0305-1846

IS - 4

ER -